Trial · NCT07880925
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
NCT07880925, Phase 1, Recruiting, dsm-firmenich Switzerland AG
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults. Trials, record NCT07880925. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880925
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
- NCT number
- NCT07880925
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 60 participants, estimated
- Lead sponsor
- dsm-firmenich Switzerland AG
- Conditions
- NAD+ Metabolism, Pharmacokinetics, Bioavailability, Healthy Adults
- Interventions
- Nicotinamide Mononucleotide (NMN), Placebo, Trigonelline Monohydrate
- First posted
- 2026-10-19
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the effect of TP daily supplementation on NAD metabolism, as measured by NAD+ concentrations in blood compared to placebo | Baseline (Day 1 pre-dose [-60 min]) and Week 4 (Day 29 ±2 days, pre-dose) | Circulating NAD+ levels in whole blood via liquid LC-MS |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose) | PK parameter for plasma trigonelline: AUC0-24 |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose through 24 hours post-dose) | PK parameter for plasma trigonelline: Cmax |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose through 24 hours post-dose) | PK parameter for plasma trigonelline: Tmax |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose through 24 hours post-dose) | PK parameter for plasma trigonelline: T½ |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose through 24 hours post-dose) | PK parameter for plasma trigonelline: AUCinf |
| Secondary | To determine the bioavailability and PK of single dose TP among different doses of TP and compared to a comparator and placebo | Over 24 hours following a single dose on Day 1 (pre-dose through 24 hours post-dose) | PK parameter for plasma trigonelline: AUC0-24:AUCinf |
| Secondary | To determine the potential accumulation of TP in plasma among different doses of TP and compared to a comparator and placebo after multiple-day dosing | Baseline (Day 1 pre-dose) and Week 4 (within 24 ±60 hours of the last dose) | Change in trough plasma trigonelline concentration |
| Secondary | To evaluate the pharmacodynamic effects of the TP on NAD metabolism over time compared to a comparator and placebo | Baseline (Day 1 pre-dose) and 4 hours post-first dose | Change in whole blood NAD-related metabolites measured via LC-MS |
| Secondary | To evaluate the pharmacodynamic effects of the TP on NAD metabolism over time compared to a comparator and placebo | Baseline (Day 1 pre-dose) and 8 hours post-first dose | Change in whole blood NAD-related metabolites measured via LC-MS |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880925
GET https://conductscience.org/api/trials/v1/NCT07880925/registered?page=2